Replies to post #125690 on Biotech Values

[DewDiligence]

AZN in-licenses PFE’s tremelimumab for undisclosed amount:

http://finance.yahoo.com/news/MedImmune-InLicenses-Cancer-prnews-988614173.html?x=0&.v=1

…MedImmune will assume global development rights to tremelimumab and Pfizer will retain the rights to use tremelimumab with specified types of combination therapies. MedImmune plans to explore tremelimumab in a number of potential cancer indications. Terms of the agreement were not disclosed.